Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday, reports UNB quoting TASS.
No serious side effects of favipiravir recorded in Russia, Healthcare Ministry says.
"Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs - Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm - Levilimab," he said, adding that Favipiravir has received a permanent registration certificate.
Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavirus.
The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.